ACADIA Pharmaceuticals Inc. (ACAD)

Compare

16.32

-0.29

(-1.75%)

At close: April 1 at 4:00:01 PM EDT

16.79

+0.47

+(2.88%)

Pre-Market: 4:26:04 AM EDT

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other biotech stocks. Biotech Sector Set for Growth Amid Innovation and Investor Interest The biotechnology sector is gaining new momentum with better market […]

Insider Monkey 7 days ago

ACAD
-1.75%
Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?

We recently published a list of 12 Best Nasdaq Stocks Under $20 to Buy Now. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other best Nasdaq stocks under $20 to buy now. The Nasdaq has had a challenging start to 2025, with the index dropping […]

Insider Monkey 15 days ago

ACAD
-1.75%
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 14, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 71,981 shares of common stock and 42,159 restricted stock units ("RSUs") to thirteen new employees under Acadia’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ empl

Business Wire 18 days ago

ACAD
-1.75%
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

SAN DIEGO, March 13, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences:

Business Wire 19 days ago

ACAD
-1.75%
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

SAN DIEGO, March 05, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age and

Business Wire 27 days ago

ACAD
-1.75%
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)

Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 27 days ago

ACAD
-1.75%
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)

ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.

Zacks 28 days ago

ACAD
-1.75%
ACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

ACADIA Pharmaceuticals ( NASDAQ:ACAD ) Full Year 2024 Results Key Financial Results Revenue: US$957.8m (up 32% from FY...

Simply Wall St. 29 days ago

ACAD
-1.75%
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

SAN DIEGO & COPENHAGEN, Denmark, March 03, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study (EUCT: 2024-514514-12-00) of ACP-711, formerly SAN711, in healthy volunteers.

Business Wire 29 days ago

SANION.ST

ACAD
-1.75%
ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

ACADIA Pharmaceuticals Inc (ACAD) reports a 32% annual revenue increase, driven by strong sales of DAYBUE and NUPLAZID, while expanding its pipeline and preparing for European market entry.

GuruFocus.com last month

ACAD
-1.75%
Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders are probably feeling a little disappointed, since its shares...

Simply Wall St. last month

ACAD
-1.75%
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference

SAN DIEGO, February 27, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 11:10 a.m. Eastern Time.

Business Wire last month

ACAD
-1.75%
ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ...

ACADIA Pharmaceuticals Inc (ACAD) reports a 93% revenue growth and strategic acquisitions, despite facing significant net losses and operational challenges.

GuruFocus.com last month

ACAD
-1.75%
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth

ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.

Zacks last month

ACAD
-1.75%
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ACAD
-1.75%
Acadia: Q4 Earnings Snapshot

SAN DIEGO (AP) — Acadia Pharmaceuticals Inc. ACAD) on Wednesday reported fourth-quarter net income of $143.7 million. The San Diego-based company said it had net income of 86 cents per share.

Associated Press Finance last month

ACAD
-1.75%
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

SAN DIEGO, February 26, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024.

Business Wire last month

ACAD
-1.75%
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?

Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.

Zacks last month

ACAD
-1.75%
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

SAN DIEGO, February 12, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 26, 2025, at 4:30 p.m. Eastern Time.

Business Wire last month

ACAD
-1.75%
High Growth Tech Stocks To Watch In February 2025

The United States market has remained flat over the past week but is up 22% over the past year, with earnings projected to grow by 15% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that are well-positioned to capitalize on technological advancements and demonstrate strong potential for revenue expansion.

Simply Wall St. last month

ACAD
-1.75%
SWTX

IREN

Performance Overview

Return	ACAD	S&P 500 (^GSPC)
YTD	-11.06%	-4.23%
1-Year	-10.62%	+7.42%
3-Year	-36.15%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ACADIA Pharmaceuticals Inc. (ACAD)

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)

ACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference

ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ...

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

Acadia: Q4 Earnings Snapshot

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

High Growth Tech Stocks To Watch In February 2025

Performance Overview